Monjuvi Injection, Powder, Lyophilized, For Solution
Product Images NDC 73535-208

Product Visual Gallery

This gallery contains 1 technical images submitted to the FDA as part of the official labeling for Monjuvi (NDC 73535-208). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Incyte Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (5 mL Vial Carton)

MONJUVI 200 mg/vial (tafasitamab-cxix) injection, powder, lyophilized, for solution vial packaging label. The label indicates intravenous route, for infusion only, single-dose vial, requires reconstitution and dilution prior to administration. Labeler is Incyte Corporation, marketed by MorphoSys US Inc. and Incyte Corp, manufactured by MorphoSys US Inc., Boston, MA. Storage instructions and detailed reconstitution guidance are provided on the carton.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.